Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-23
2005-08-23
Andres, Janet (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000, C530S351000, C424S093200, C424S569000
Reexamination Certificate
active
06933278
ABSTRACT:
Embodiments of this invention include methods for decreasing hypertension in mammals subjected to adverse cardiovascular fetal programming or a long-term adverse postnatal environment. Fetal programming can result from adverse intrauterine conditions, including growth retardation or undernutrition. Adverse postnatal environments include either hypocaloric or hypercaloric nutrition. Decreasing hypertension is such mammals can be accomplished by administering an agent that increases the effective amount of a growth hormone. Such agents can include a growth hormone, an agent that increases the effective concentration of a growth hormone in the mammal, or an agent that decreases inhibition of a growth hormone's effects. Such agents can be used either alone, or in combination with other anti-hypertensive agents.
REFERENCES:
patent: 97/38709 (1997-10-01), None
Baker, D.J. P., Outcome of low birthweight (1994), Hormone Research 42:223-230.
Job et al., Follow-up of three years of treatment with growth hormone and of one post-treatment year, in children with severe growth retardation of intrauterine onset (1996), Pediatric Research 39: 354-359.
Gudmundur, Johannsson, “Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure”, Journal of Clinical Endocrinology and Metabolism, vol. 82, No. 3, (1997).
Rosen, Thord, “Cardiovascular Risk Factors in Adult Patients with Growth Hormone Deficiency”, Acta Endocrinologica, 1993, 129; 195-200.
Jorgensen, Jens O.L., “Adult Growth Hormone Deficiency”, Horm. Res. 1994; 42:235-241.
Salomon, Franco, “The Effects of Treatment With Recombinant Human Growth Hormone on Body Composition and Metabolism in Adults with Growth Hormone Deficiency”, The New England Journal of Medicine, vol. 321, No. 26: 1797-1803, Dec. 28, 1989.
Lopez-Velasco, Rasario, “Cardiac Involvement in Acromegaly: Specific Myocardiopathy or Consequence of Systemic Hypertension”, Journal of Clinical Endocrinology and Metabolism, vol. 82, No. 4, 1047-1053, (1997).
Sas, Theo, “Body Composition, Blood Pressure, Lipid Metabolism before and during Long-Term Grwoth Hormone (GH) Treatment in Children with Short Stature Born Small for Gestational Age Either with or without GH Deficiency”, Journal of Clinical Endocrinology and Metabolism, vol. 85, No. 10: 3786-3792, (2000).
Coves, Maria J., Clinical Note-Antihypertension Therapy with Guanfacine Induces Elevated Plasma Growth Hormone Levels In Diabetic Patients, Journal of Medicine, vol. 20, Nos. 3 & 4, 1989, 291-297, (1989).
Bengtsson, B.A., “Untreated Growth Hormone Deficiency Explains Premature Mortality in Patients with Hypopituitarism”, Growth Hormone and IGF Resarch, 1998, 8 (Suppl. A), 77-80.
Salomon et al, “The Effects of Treatment . . . ,” The New England Journal of Medicine, vol. 321, No. 26 pp. 1797-1803 (1989).
Rosen et al, “Cardiovascular risk factors . . . ,” Acta Endocrinologica, vol. 129, pp. 195-200 (1993).
Breier Bernhard H. H.
Ikenasio Betina A.
Vickers Mark H.
Andres Janet
Auckland Uniservices Limited
Fliesler & Meyer LLP
Seharaseyon Jegatheesan
LandOfFree
Treatment of hypertension using growth hormone in mammals... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hypertension using growth hormone in mammals..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hypertension using growth hormone in mammals... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487522